Loury David J,Hedrick Eric,Elias Laurence,Mody Tarak D,Fyfe Gwen,Buggy Joseph J
申请号：
NZ71737311
公开号：
NZ717373A
申请日:
2011.06.03
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Disclosed is use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765), in the manufacture of a medicament for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has already received at least one prior therapy for MZL.
